Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
The global generics firm will rebrand Matrix, its Indian arm, as "Mylan," as it anticipates launching its prescription products in India under the Mylan label.
You may also be interested in...
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.
After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout
MUMBAI - The potential of the Indian pharmaceutical market to double from the present $8 billion to $15 billion in the next five years led Abbott last week to strike the most richly valued deal for Piramal Healthcare's generic drug businesses, but the action for a share of the Indian market is set to accelerate further as Mylan - the third largest generic company in the world and the largest in the U.S. with sales exceeding $5 billion - is preparing to enter the Indian formulations market
Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on
MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market